Lyxumia (Lixisenatide) Monitoring and Diabetes Control Panel
This lab panel tracks A1c, glucose patterns, insulin resistance, kidney safety, and lipids to monitor diabetes control while using Lyxumia.
This panel bundles multiple biomarker tests in one order—your report explains how results fit together.
If you are taking Lyxumia (lixisenatide) or considering a GLP-1 medication plan, one number rarely tells the whole story. This lab panel bundles several diabetes and cardiometabolic markers into one draw so you can see whether your day-to-day glucose, longer-term A1c, insulin resistance signals, kidney safety markers, and lipids are moving in the same direction.
Do I need this panel?
You may want this lab panel if you are using Lyxumia (lixisenatide) and you are unsure whether your current plan is improving glucose control beyond what you see on a home meter or CGM. It is also useful if your A1c and fasting glucose do not seem to “match,” if you have hit a weight-loss or glucose plateau, or if you are changing your diet in a way that could shift lipids and insulin needs.
This panel is designed for monitoring, not just diagnosis. It helps you check multiple moving parts at once: short-term glucose (fasting glucose), longer-term average glucose exposure (A1c), insulin resistance patterns (fasting insulin with calculated indices when available), and safety/organ markers that matter in diabetes care (kidney function and urine albumin screening), plus cardiovascular risk markers (lipids).
If you already have diabetes or prediabetes, repeating the same panel over time can be more informative than chasing single tests. Your clinician can use these results to adjust medication timing/dose, nutrition strategy, and follow-up testing. This panel supports clinician-directed care and does not diagnose conditions by itself.
Reference ranges and calculated indices can vary by laboratory; your results should be interpreted in context of your medications (including GLP-1 therapy), diet, and recent illness.
Lab testing
Order labs to measure Lyxumia (Lixisenatide) Monitoring and Diabetes Control Panel
from $426.67 at Quest Diagnostics
About 1 week
Schedule online — results typically within a week
Clear next steps
Guidance included, with follow-up care available
HSA / FSA
Eligible for pre-tax health spending accounts
Get this panel with Vitals Vault
Vitals Vault makes it straightforward to order a diabetes monitoring lab panel when you want a clearer picture than a single A1c. You can use this panel to establish a baseline before starting Lyxumia, to check your response after a dose change, or to monitor trends during a nutrition and weight-management reset.
After your blood draw, you can review results in one place and focus on patterns across markers—such as whether fasting glucose is improving but A1c is lagging, or whether glucose control is better but lipids are shifting. If you want help connecting the dots, PocketMD can help you translate a multi-marker panel into practical next steps to discuss with your clinician.
If you are building a longer-term monitoring plan, you can repeat this panel at consistent intervals so your trend lines are comparable, or add a more comprehensive diabetes package when you need broader surveillance.
- Panel-style results that are easier to interpret as a set, not isolated numbers
- Designed for GLP-1 users who want both glucose control and safety monitoring
- PocketMD support to help you understand patterns and questions to bring to your clinician
- Repeat-friendly: consistent markers for trend tracking over time
Key benefits of the Lyxumia (Lixisenatide) Monitoring and Diabetes Control Panel
- Shows both short-term and long-term glucose control by pairing fasting glucose with A1c.
- Helps explain “mismatched” results (for example, normal fasting glucose with elevated A1c) by adding context markers.
- Tracks insulin resistance signals that can change with weight loss, diet shifts, and GLP-1 therapy.
- Includes kidney screening markers that matter for diabetes safety monitoring and medication planning.
- Adds lipid testing to monitor cardiometabolic risk, which may shift during weight loss or dietary changes.
- Supports medication check-ins after starting Lyxumia or changing dose, especially when progress plateaus.
- Creates a repeatable baseline so you can compare trends across visits instead of relying on one-off numbers.
What is the Lyxumia (Lixisenatide) Monitoring and Diabetes Control Panel?
This is a multi-biomarker lab panel designed to monitor diabetes control and related metabolic health while you are using Lyxumia (lixisenatide), a GLP-1 receptor agonist. Instead of measuring one analyte, the panel combines several categories of tests that work better together than alone.
At a high level, the panel covers:
• Glycemia over different time windows: fasting glucose reflects your current baseline, while hemoglobin A1c (HbA1c) reflects average glucose exposure over roughly the prior 2–3 months.
• Insulin resistance and metabolic signaling: fasting insulin (and derived indices when available) can help you understand whether your body needs a lot of insulin to keep glucose controlled, which is a common driver of prediabetes and type 2 diabetes patterns.
• Kidney health and diabetes complications screening: serum creatinine with estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (ACR) are commonly used to screen for early kidney stress related to diabetes and to guide medication choices.
• Cardiometabolic risk: a lipid panel (cholesterol fractions and triglycerides) helps you track cardiovascular risk factors that often travel with insulin resistance and can change during weight loss or diet transitions.
Because Lyxumia can improve post-meal glucose and appetite regulation, you often want to confirm that improvements you feel (or see on a CGM) are also showing up in longer-term markers and safety markers. This panel is built to support that full-picture check.
What do my panel results mean?
When results trend low (or lower than expected)
In this panel, “low” usually shows up as lower glucose and A1c compared with your prior baseline, sometimes alongside lower fasting insulin. That pattern often suggests improved glycemic control and reduced insulin demand, which can happen with GLP-1 therapy, weight loss, improved sleep, and nutrition changes. However, very low glucose values—especially if paired with symptoms like shakiness, sweating, confusion, or nighttime awakenings—can signal hypoglycemia risk, particularly if you also use insulin or sulfonylureas. Low creatinine is usually not a concern by itself, but kidney markers should be read as a set (creatinine, eGFR, and urine albumin) rather than a single number.
When results look optimal and consistent
An “optimal” pattern is consistency across the panel: fasting glucose and A1c moving toward your clinician-defined targets, fasting insulin and insulin-resistance indices improving (or staying appropriate for you), kidney markers stable (eGFR not declining and urine albumin not elevated), and lipids not worsening as you lose weight or adjust diet. This kind of alignment is reassuring because it suggests your day-to-day glucose control is translating into better longer-term exposure and that key safety markers are staying steady. If you are early in treatment, optimal results also give you a clean baseline to compare against after dose changes.
When results trend high (or don’t improve together)
A “high” pattern can mean different things depending on which markers are elevated together. High A1c with high fasting glucose usually points to persistent hyperglycemia and may mean your current plan is not sufficient or needs more time and support. High A1c with near-normal fasting glucose can happen when post-meal spikes are driving the average, when glucose is variable, or when red blood cell factors affect A1c interpretation—this is a common reason to look at the panel as a whole rather than one result. Elevated fasting insulin (with or without elevated glucose) can suggest ongoing insulin resistance. If urine albumin is elevated or eGFR is declining, that is a kidney-safety signal that deserves timely clinician follow-up, especially in the context of diabetes.
Factors that influence this panel
Your results can shift based on timing, medications, and recent physiology. Lyxumia and other GLP-1 therapies can improve post-meal glucose and reduce appetite, which may lower glucose and A1c over time; the full A1c effect often lags behind day-to-day improvements. Diet changes (including very low-carb or high-fat patterns) can lower glucose while raising LDL cholesterol in some people, so pairing glycemic markers with lipids is important. Dehydration, intense exercise, and certain supplements can affect creatinine and eGFR interpretation. A1c can be misleading in conditions that change red blood cell turnover (for example, iron deficiency anemia, recent blood loss, or hemoglobin variants). Illness, steroids, poor sleep, and stress can raise glucose and insulin needs. Bring your medication list (including insulin, sulfonylureas, steroids, and thyroid meds), recent weight changes, and CGM/home glucose patterns when you review your panel.
What’s included in this panel
- Absolute Band Neutrophils
- Absolute Basophils
- Absolute Blasts
- Absolute Eosinophils
- Absolute Lymphocytes
- Absolute Metamyelocytes
- Absolute Monocytes
- Absolute Myelocytes
- Absolute Neutrophils
- Absolute Nucleated Rbc
- Absolute Plasma Cells
- Absolute Prolymphocytes
- Absolute Promyelocytes
- Absolute Reactive Lymphocytes
- Albumin
- Albumin/Creatinine Ratio, Random Urine
- Albumin/Globulin Ratio
- Albumin, Urine
- Alkaline Phosphatase
- Alt
- Amorphous Sediment
- Amylase
- Appearance
- Ast
- Bacteria
- Band Neutrophils
- Basophils
- Bilirubin
- Bilirubin, Total
- Blasts
- Bun/Creatinine Ratio
- C-Peptide
- Calcium
- Calcium Oxalate Crystals
- Carbon Dioxide
- Casts
- Chloride
- Chol/Hdlc Ratio
- Cholesterol, Total
- Color
- Creatinine
- Creatinine, Random Urine
- Crystals
- Cystatin C
- Egfr
- Eosinophils
- Globulin
- Glucose
- Granular Cast
- Hdl Cholesterol
- Hdl Large
- Hematocrit
- Hemoglobin
- Hemoglobin A1C
- Hyaline Cast
- Insulin
- Ketones
- Ldl-Cholesterol
- Ldl/Hdl Ratio
- Ldl Medium
- Ldl Particle Number
- Ldl Pattern
- Ldl Peak Size
- Ldl Small
- Leukocyte Esterase
- Lipase
- Lymphocytes
- Magnesium
- Mch
- Mchc
- Mcv
- Metamyelocytes
- Monocytes
- Mpv
- Myelocytes
- Neutrophils
- Nitrite
- Non Hdl Cholesterol
- Nucleated Rbc
- Occult Blood
- Ph
- Phosphate (As Phosphorus)
- Plasma Cells
- Platelet Count
- Potassium
- Prolymphocytes
- Promyelocytes
- Protein
- Protein, Total
- Rbc
- Rdw
- Reactive Lymphocytes
- Red Blood Cell Count
- Renal Epithelial Cells
- Sodium
- Specific Gravity
- Squamous Epithelial Cells
- T3, Free
- T4, Free
- Transitional Epithelial Cells
- Triglycerides
- Triple Phosphate Crystals
- Tsh
- Urea Nitrogen (Bun)
- Uric Acid Crystals
- Vitamin D, 25-Oh, D2
- Vitamin D, 25-Oh, D3
- Vitamin D, 25-Oh, Total
- Wbc
- White Blood Cell Count
- Yeast
Similar tests and panels to consider
Frequently Asked Questions
Do I need to fast for this panel?
Fasting is usually recommended because the panel commonly includes fasting glucose, fasting insulin, and a lipid panel. A typical target is 8–12 hours with water only, unless your clinician has given different instructions. Keep taking medications as prescribed unless your clinician tells you to hold them, and note the time of your last dose when you review results.
How often should I repeat this monitoring panel while using Lyxumia?
Many people repeat key diabetes monitoring labs every 8–12 weeks when starting or adjusting therapy because A1c reflects roughly 2–3 months of glucose exposure. If you are stable, your clinician may monitor less frequently. The most useful approach is repeating at consistent intervals and comparing trends rather than reacting to a single draw.
Why can my fasting glucose look better but my A1c still be high?
Fasting glucose is a snapshot, while A1c is a longer-term average. You can have improved fasting numbers but still have post-meal spikes that keep A1c elevated, or you may be early in a treatment change and A1c has not “caught up” yet. Less commonly, A1c can be skewed by red blood cell factors (like iron deficiency anemia). Looking at the whole panel and your home glucose/CGM data helps clarify the reason.
What kidney markers in this panel matter most for diabetes monitoring?
Creatinine with eGFR estimates filtration function, while the urine albumin-to-creatinine ratio (ACR) screens for albumin leakage that can be an early sign of diabetic kidney stress. ACR can be temporarily elevated after intense exercise, fever, or a urinary tract infection, so your clinician may repeat it if it is abnormal.
Can GLP-1 medications like lixisenatide affect cholesterol and triglycerides?
They can, indirectly. Weight loss, appetite changes, and diet shifts often change triglycerides and HDL, and LDL can move up or down depending on your diet pattern and genetics. That is why pairing glucose markers with a lipid panel is helpful—your plan can be working for glycemia while still needing lipid-focused adjustments.
Is it better to order this panel than to order A1c alone?
A1c alone is useful, but it does not tell you whether fasting glucose, insulin resistance signals, kidney screening markers, and lipids are improving or drifting. If you are monitoring a GLP-1 plan, troubleshooting a plateau, or trying to reduce long-term risk, a bundled panel often gives you more actionable context than a single marker.
What should I bring to a results review so the panel is interpreted correctly?
Bring your medication list and doses (including insulin or sulfonylureas if used), recent weight changes, your typical diet pattern, alcohol intake, exercise changes, and home glucose/CGM summaries (especially post-meal patterns). Also mention recent illness, steroid use, dehydration, or heavy training, since these can shift glucose and kidney markers.